<DOC>
	<DOCNO>NCT01482377</DOCNO>
	<brief_summary>This dose-escalating study consist 3 part ( A , B C ) evaluate safety , pharmacokinetics efficacy RO5479599 , alone combination cetuximab erlotinib , participant metastatic and/or locally advance malignant HER3-positive solid tumor . Cohorts participant receive escalate dos intravenous RO5479599 monotherapy ( Part A ) combination cetuximab ( Part B ) erlotinib ( Part C ) follow extension phase part . In image substudy , participant receive one two dose zirconium-89-labeled RO5479599 ( 89ZrRO5479599 ) addition unlabeled RO5479599 evaluate vivo biodistribution organ pharmacokinetics RO5479599 .</brief_summary>
	<brief_title>A Study RO5479599 Alone Combination With Cetuximab Erlotinib Participants With Metastatic and/or Locally Advanced Malignant Human Epidermal Growth Factor Receptor ( HER3 ) Expressing Solid Tumors Epithelial Cell Origin</brief_title>
	<detailed_description />
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>All Parts ( A , B C ) European Cooperative Oncology Group ( ECOG ) performance status 02 Histologically confirm metastatic and/or locally advance malignant HER3expressing solid tumor epithelial origin Availability tissue willingness perform fresh pretreatment biopsy Participants standard therapy exist All acute toxic effect prior radiotherapy , chemotherapy surgical procedure must resolve Grade le equal ( &lt; /= 1 ) , except alopecia Grade 2 peripheral neuropathy Adequate hematological , renal liver function Participants Gilbert 's syndrome eligible study Part B extension cohort : In addition inclusion criterion , participant eligible metastatic and/or locally advance nonsmall cell lung cancer squamous cell carcinoma head neck colorectal cancer ( wild type positive epidermal growth factor receptor [ EGFR ] expression ) Part C extension cohort : In addition inclusion criterion , participant eligible metastatic and/or locally advance squamous nonsmall cell lung cancer Known clinically suspect central nervous system ( CNS ) primary tumor metastases include leptomeningeal metastasis . History clinical evidence CNS metastases unless previously treat , asymptomatic requirement steroid enzymeinducing anticonvulsant last 14 day Evidence significant uncontrolled concomitant diseases disorder Active uncontrolled infection Known Human immuno deficiency virus ( HIV ) infection Therapy antibody immunotherapy concurrently within 14 day prior first dose study drug Regular immunosuppressive therapy Concurrent high dose systemic corticosteroid ( great ( &gt; ) 20 milligram per day [ mg/day ] dexamethasone equivalent &gt; 7 consecutive day )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>